Ilan Daskal is recorded as CFO at Viavi Solutions Inc. (VIAV). Ilan Daskal was last confirmed as CFO at Bio-Rad Laboratories, Inc. (BIO) in a filing dated March 27, 2024. Earlier roles on record: CFO at Bio-Rad Laboratories, Inc. (BIO) until November 6, 2023. Bio-Rad Laboratories, Inc. reported in an 8-K filed February 14, 2024 that Ilan Daskal resigned as Executive Vice-President, Chief Financial Officer, effective November 6, 2023. Viavi Solutions Inc. reported in an 8-K filed October 18, 2023 that Ilan Daskal was appointed Executive Vice President and Chief Financial Officer, effective November 7, 2023. Bio-Rad Laboratories, Inc. reported in an 8-K filed October 17, 2023 that Ilan Daskal resigned as Executive Vice-President, Chief Financial Officer, effective November 6, 2023. The proxy statement of Viavi Solutions Inc. reports total compensation of $4,803,607 for Ilan Daskal in fiscal 2026, including a base salary of $570,003. Disclosed compensation is on record for 8 fiscal years. Ilan Daskal has spoken on 26 earnings calls across 2 companies, most recently for Viavi Solutions Inc. on August 5, 2026. Those appearances were for Bio-Rad Laboratories, Inc. (BIO) and Viavi Solutions Inc. (VIAV). Viavi Solutions Inc. is classified in the Communication Equipment industry within the Technology sector. Other companies whose calls Ilan Daskal spoke on are classified in the Healthcare sector. Other leadership on record at Viavi Solutions Inc. includes Donald Colvin (Board Member), Doug Gilstrap (Board Member), Douglas Gilstrap (Board Member) and 7 others.
“As previously disclosed, effective at the close of business on November 6, 2023, Ilan Daskal resigned from his position as the Company’s Executive Vice-President, Chief Financial Officer and the Company’s principal financial officer in order to pursue other opportunities.”
Bio-Rad Laboratories, Inc. Form 8-K, filed February 14, 2024
· Read the filing
“effective November 7, 2023, Ilan Daskal would join the Company as Executive Vice President and Chief Financial Officer.”
Viavi Solutions Inc. Form 8-K, filed October 18, 2023
· Read the filing
Ilan Daskal on recent calls
“Now, I would like to review the results of the fourth quarter of fiscal year 2026 net revenue for the quarter was 443.1 million dollars which is above the high end of our guidance range of 427 to 437 million dollars revenue was up 8.9 percent sequentially and on a year-over-year basis was up 52.5 percent operating…”
“Now I would like to review the results of the third quarter of fiscal year 2026. net revenue for the quarter was 406.8 million dollars which is above the high end of our guidance range of 386 and 400 million dollars revenue was up 10.2 percent sequentially and on a year-over-year basis was up 42.8 percent operating…”
“Now I would like to review the results of the second quarter of fiscal year 2026. Net revenue for the quarter was $369.3 million, which is at the high end of our guidance range of $360 and $370 million. dollars.”
“Now I would like to review the results of the first quarter of fiscal year 2026. Net revenue for the quarter was $299.1 million, which is above the high end of our guidance range of $290 and $298 million.”
“Now I would like to review the results of the fourth quarter of fiscal year 2025. Net revenue for the quarter was 290.5 million dollars which is at the the high end of our guidance range of 278 to 290 million dollars.”
